CELECOXIB- celecoxib capsule

Land: USA

Språk: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv ingrediens:

CELECOXIB (UNII: JCX84Q7J1L) (CELECOXIB - UNII:JCX84Q7J1L)

Tilgjengelig fra:

Jubilant Cadista Pharmaceuticals Inc.

INN (International Name):

CELECOXIB

Sammensetning:

CELECOXIB 50 mg

Administreringsrute:

ORAL

Resept typen:

PRESCRIPTION DRUG

Indikasjoner:

Celecoxib capsules are indicated. For the management of the signs and symptoms of OA [see Clinical Studies (14.1)] For the management of the signs and symptoms of RA [see Clinical Studies (14.2) ] For the management of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3)] For the management of the signs and symptoms of AS [see Clinical Studies (14.4) ] For the management of acute pain in adults [see Clinical Studies (14.5) ] For the management of primary dysmenorrhea [see Clinical Studies (14.5)]   Celecoxib is contraindicated in the following patients: - Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see Warnings and Precautions (5.7, 5.9)]. Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see Warnings and Precautions (5.7, 5.9)]. - History of asthma, urticaria, or other allergic-type reactions after

Produkt oppsummering:

Celecoxib capsules 50 mg are white opaque colored cap and body, size '4' hard gelatin capsules, printed in red ink on cap and body with marking C 561 containing off white to white granular powder, supplied as: Bottle of 30’s count   (child-resistant closure)     NDC 59746-561-30 Bottle of 60’s count   (child-resistant closure)     NDC 59746-561-60 Bottle of 100’s count (child-resistant closure)     NDC 59746-561-01 Bottle of 1000’s count                                         NDC 59746-561-10 Celecoxib capsules 100 mg are white opaque colored cap and body, size '3' hard gelatin capsules, printed in blue ink on cap and body with marking C 562 containing off white to white granular powder, supplied as: Bottle of 30’s count   (child-resistant closure)    NDC 59746-562-30 Bottle of 100’s count (child-resistant closure)    NDC 59746-562-01 Bottle of 500’s count                                          NDC 59746-562-05 Bottle of 1000’s count                                        NDC 59746-562-10 Celecoxib capsules 200 mg are white opaque colored cap and body, size '2' hard gelatin capsules, printed in yellow ink on cap and body with marking C 563 containing off white to white granular powder, supplied as: Bottle of 30’s count   (child-resistant closure)    NDC  59746-563-30 Bottle of 100’s count (child-resistant closure)    NDC  59746-563-01 Bottle of 500’s count                                          NDC  59746-563-05 Bottle of 1000’s count                                        NDC  59746-563-10 Celecoxib capsules 400 mg are white opaque colored cap and body, size '0el' hard gelatin capsules, printed in green ink on cap and body with marking C 564 containing off white to white granular powder, supplied as: Bottle of 30’s count   (child-resistant closure)     NDC  59746-564-30 Bottle of 60’s count   (child-resistant closure)     NDC  59746-564-60 Bottle of 100’s count (child-resistant closure)     NDC  59746-564-01 Bottle of 400’s count                                           NDC  59746-564-67 Storage Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

Autorisasjon status:

Abbreviated New Drug Application

Informasjon til brukeren

CELECOXIB - CELECOXIB CAPSULE
Jubilant Cadista Pharmaceuticals Inc.
----------
MEDICATION GUIDE FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAIDS)
What is the most important information I should know about medicines
called Nonsteroidal Anti-
inflammatory Drugs (NSAIDs)?
NSAIDs can cause serious side effects, including:
•
Increased risk of a heart attack or stroke that can lead to death.
This risk may happen early in
treatment and may increase:
•
with increasing doses of NSAIDs
•
with longer use of NSAIDs
Do not take NSAIDs right before or after a heart surgery called a
“coronary artery bypass graft
(CABG)."
Avoid taking NSAIDs after a recent heart attack, unless your
healthcare provider tells you to. You may
have an increased risk of another heart attack if you take NSAIDs
after a recent heart attack.
•
Increased risk of bleeding, ulcers, and tears (perforation) of the
esophagus (tube leading from the
mouth to the stomach), stomach and intestines:
•
anytime during use
•
without warning symptoms
•
that may cause death
The risk of getting an ulcer or bleeding increases with:
○ past history of stomach ulcers, or stomach or intestinal bleeding
with use of NSAIDs
○ taking medicines called “corticosteroids”, “antiplatelet
drugs”, “anticoagulants”, “SSRIs” or
“SNRIs”
○ increasing doses of NSAIDs
○ older age
○ longer use of NSAIDs
○ poor health
○ smoking
○ advanced liver disease
○ drinking alcohol
○ bleeding problems
NSAIDs should only be used:
•
exactly as prescribed
•
at the lowest dose possible for your treatment
•
for the shortest time needed
What are NSAIDs?
NSAIDs are used to treat pain and redness, swelling, and heat
(inflammation) from medical conditions
such as different types of arthritis, menstrual cramps, and other
types of short-term pain.
Who should not take NSAIDs?
Do not take NSAIDs:
•
if you have had an asthma attack, hives, or other allergic reaction
with aspirin or any other
NSAIDs.
•
right before or after heart bypass surgery.
Before tak

Preparatomtale

CELECOXIB - CELECOXIB CAPSULE
JUBILANT CADISTA PHARMACEUTICALS INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CELECOXIB CAPSULES
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CELECOXIB
CAPSULES.
CELECOXIB CAPSULES, FOR ORAL USE
INITIAL U.S. APPROVAL: 1998
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) CAUSE AN INCREASED RISK
OF SERIOUS
CARDIOVASCULAR THROMBOTIC EVENTS, INCLUDING MYOCARDIAL INFARCTION AND
STROKE, WHICH
CAN BE FATAL. THIS RISK MAY OCCUR EARLY IN THE TREATMENT AND MAY
INCREASE WITH
DURATION OF USE. (5.1)
CELECOXIB CAPSULES ARE CONTRAINDICATED IN THE SETTING OF CORONARY
ARTERY BYPASS
GRAFT (CABG) SURGERY. (4, 5.1)
NSAIDS CAUSE AN INCREASED RISK OF SERIOUS GASTROINTESTINAL (GI)
ADVERSE EVENTS
INCLUDING BLEEDING, ULCERATION, AND PERFORATION OF THE STOMACH OR
INTESTINES, WHICH
CAN BE FATAL. THESE EVENTS CAN OCCUR AT ANY TIME DURING USE AND
WITHOUT WARNING
SYMPTOMS. ELDERLY PATIENTS AND PATIENTS WITH A PRIOR HISTORY OF PEPTIC
ULCER DISEASE
AND/OR GI BLEEDING ARE AT GREATER RISK FOR SERIOUS GI EVENTS. (5.2)
RECENT MAJOR CHANGES
Warnings and Precautions (5.1, 5.4) 6/2018
Warnings and Precautions (5.2) 5/2019
INDICATIONS AND USAGE
Celecoxib capsules are nonsteroidal anti-inflammatory drug indicated
for:
Osteoarthritis (OA) (1.1)
Rheumatoid Arthritis (RA) (1.2)
Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older
(1.3)
Ankylosing Spondylitis (AS) (1.4)
Acute Pain (AP) (1.5)
Primary Dysmenorrhea (PD) (1.6)
DOSAGE AND ADMINISTRATION
Use the lowest effective dosage for shortest duration consistent with
individual patient treatment goals
(2.1)
OA: 200 mg once daily or 100 mg twice daily (2.2, 14.1)
RA: 100 mg to 200 mg twice daily (2.3, 14.2)
JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily
in patients more than 25 kg (2.4,
14.3)
AS: 200 mg once daily single dose o